Chief Executive of Vectura Group to step down

Chris Blackwell will leave the company on 30 June 2015

After 12 years with Vectura, a UK-based developer of products to treat airways related diseases such as asthma and chronic obstructive pulmonary disease (COPD), Chris Blackwell will step down as Chief Executive on 30 June.

Blackwell, who joined the company before the Initial Public Offering (IPO) and will assist the Board in the search for his successor, feels that 'now is the right time to move on'.

You may also like

Drug Delivery

Optimising dry powder inhaler programmes through formulation

The use of dry powder formulations originally focused on respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD) because pulmonary administration of the active pharmaceutical ingredient (API) provides direct and rapid action. However, direct delivery to the lung is also a quick and efficient way of administering non-respiratory drugs systemically without have to wait for them to be absorbed through the gut
Research & Development

Vectura partners with Monash University on inhaled oxytocin

The inhalation formula will be used instead of the current injection method
Drug Delivery

Vectura and Propeller Health link up to develop digitally-connected inhalers for chronic respiratory diseases

The two firms are also discussing additional connected strategies for other proprietary respiratory devices in Vectura’s pipeline
Research & Development

Vectura and UCB form inflammatory disease collaboration

Will focus on bringing to clinical proof-of-concept a UCB-generated biological therapy targeting a key molecule in the immune system
Regulatory

US Pharmacopeia details mass spectrometry guidelines to advance biologics impurity control

The new chapter aims to standardise the use of mass spectrometry-based analysis in the biopharmaceutical industry, which can be used to detect impurities in cell and gene therapies, antibodies and other biologics
You need to be a subscriber to read this article.
Click here to find out more.
Research & Development

Hybrid interferons: developing a novel drug class

With many hurdles to overcome, establishing a new drug candidate is a long process — particularly if you are a smaller biotech company with limited resources. These challenges can be further amplified if the candidate being developed is of an entirely novel drug class
Distribution

2BScientific expands its life science product supply service to Europe with new German facility

The facility in Munich will serve the European market with life science products, including in vitro diagnostic (IVD) reagents, buffers, biomaterials and antibodies
Subscribe now